Brief Summary
This trial represents a single institution phase I/II pilot study with the primary objective of establishing the safety and feasibility of generating and infusing ML NK cells after TCRαβ haplo-HCT.
Protocol Interventions
Drug: Plerixafor, Biological: Granulocyte Colony-Stimulating Factor